(EMAILWIRE.COM<\/a>, May 24, 2025 ) Small interfering RNA (siRNA) Therapeutics Market to Hit USD 39.19 Bn by 2032<\/p>\n Small Interfering RNA (SIRNA) Therapeutics Market is expected to reach US$ 39.19 Bn. at a CAGR of 17.5 % during the forecast period (2024-2030).<\/p>\n Explore additional details by clicking the link provided: https:\/\/www.maximizemarketresearch.com\/request-sample\/91788\/<\/a> <\/p>\n About the Market<\/p>\n SIRNA Therapeutics Market is expanding rapidly, driven by technology developments, a shift toward customized treatment, and increased research spending. While problems like as high production costs and regulatory hurdles remain, continual advancements and expanding applications provide encouraging possibilities for the future of RNA-based therapeutics.<\/p>\n Small Interfering RNA (siRNA) Therapeutics Market Segment Analysis<\/p>\n In 2024, Nanoparticle-Based Systemic Therapy Segment Held the Dominant Position with A Share of Above 53% While Pharmaceutical and Biotechnology Companies Segment Dominated the Small interfering RNA (siRNA) Therapeutics Market In 2024 and accounted for 56.57% Of the Global Revenue Share.<\/p>\n By Type<\/p>\n Liposome Based Systemic Therapy By Applications<\/p>\n Hospital, Research Institutions For a deeper understanding, click on the link below: https:\/\/www.maximizemarketresearch.com\/request-sample\/91788\/<\/a> <\/p>\n Small Interfering RNA (siRNA) Therapeutics Market Regional Insights<\/p>\n In 2024, North America held the largest revenue share in the Small interfering RNA (siRNA) Therapeutics Market, contributing approximately 41%, followed by Europe as the second-largest region with around 30% of the market share. These regions dominate the market because of their advanced healthcare systems, major biotechnology investments, and favorable regulatory regimes that encourage the research and marketing of siRNA-based treatments.<\/p>\n Market key players Fueling industry evolution<\/p>\n These companies are leading the Small interfering RNA (siRNA) Therapeutics Market, demonstrating strong financial performance and strategic investments in product development and market expansion:<\/p>\n Sanofi Genzyme (Sanofi) – $4.6 billion To dive into the specifics, click the below link: https:\/\/www.maximizemarketresearch.com\/market-report\/global-small-interfering-rna-sirna-therapeutics-market\/91788\/<\/a> <\/p>\n New Related Markets Published by Maximize Market Research.<\/p>\n Gene Therapy Market<\/a>: Gene Therapy Market size was valued at USD 10.03 Billion in 2024 and the total Gene Therapy revenue is expected to grow at a CAGR of 16% from 2025 to 2032, reaching nearly USD 32.89 Billion.<\/p>\n Prostate Cancer Therapeutics Market<\/a>: Prostate Cancer Therapeutics Market size was valued at USD 18.12Billion in 2023 and the total Global Prostate Cancer Therapeutics Market revenue is expected to grow at a CAGR of 7.3% from 2024 to 2030, reaching nearly USD 29.73Billion.<\/p>\n![](\"http:\/\/www.emailwire.com\/files\/pr_images\/mid_thumbs\/1_1746782520_1148729.jpg\" "\\"Small")
Small Interfering RNA (SIRNA) Therapeutics Market<\/span><\/a><\/p>\n<\/div>\n
\nNanoparticle Based Systemic Therapy
\nOther<\/p>\n
\nPharmaceutical and Biotechnology Companies
\nAcademic Institutions
\nOther<\/p>\n
\nAlnylam Pharmaceuticals – $1.4 billion
\nOPKO Health, Inc. – $863.5 million
\nSilence Therapeutics – $31.5 million
\nArbutus Biopharma – $18.1 million<\/p>\n